Jazz Pharmaceuticals
JAZZ
339 hedge funds and large institutions have $7.07B invested in Jazz Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 127 increasing their positions, 121 reducing their positions, and 52 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
5% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 121
6% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 52
2% less funds holding
Funds holding: 345 → 339 (-6)
11% less capital invested
Capital invested by funds: $7.92B → $7.07B (-$844M)
13% less call options, than puts
Call options by funds: $101M | Put options by funds: $117M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$104M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$31.4M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$29.5M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$25M |
| 5 |
Renaissance Technologies
New York
|
+$24.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
-$89.7M |
| 2 |
NC
Nicholas Company
Milwaukee,
Wisconsin
|
-$83.2M |
| 3 |
HCM
Hoplite Capital Management
New York
|
-$77.5M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$55.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$49.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OA
376
Oak Associates
Akron,
Ohio
| – | -$211K | -1,500 | Closed |
|
377
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$211K | -1,498 | Closed |
|
|
ECM
378
ETrade Capital Management
Arlington,
Virginia
| – | -$201K | -1,430 | Closed |
|
|
WCA
379
Waratah Capital Advisors
Toronto,
Ontario, Canada
| – | -$200K | -1,425 | Closed |
|
|
GBT
380
Grove Bank & Trust
Miami,
Florida
| – | -$48K | -345 | Closed |
|
381
Simplex Trading
Chicago,
Illinois
| – | -$34K | -273 | Closed |
|
|
WRM
382
Westport Resources Management
Westport,
Connecticut
| – | -$21K | -150 | Closed |
|
|
CCS
383
Crosspoint Capital Strategies
Orinda,
California
| – | -$23K | -142 | Closed |
|
|
CFA
384
Carroll Financial Associates
Charlotte,
North Carolina
| – | -$14K | -100 | Closed |
|
385
ClearBridge Investments
New York
| – | -$14K | -100 | Closed |
|
|
DBT
386
Dubuque Bank & Trust
Dubuque,
Iowa
| – | -$6K | -45 | Closed |
|
|
ZB
387
Zions Bancorporation
Salt Lake City,
Utah
| – | -$1K | -10 | Closed |
|
|
QCG
388
Quadrant Capital Group
Cincinnati,
Ohio
| – | +$1.74K | +14 | New |
|
JAZZ Hedge Fund Activity: Q1 2016 in Review
339 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2016, worth a combined $7.07B — down 11% from $7.92B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of JAZZ and 49 opened new positions — a net loss of 3 holders — while 121 trimmed existing stakes and 127 added.
The largest buyer was Fidelity International, adding an estimated $104M. The largest seller was Herndon Capital Management, cutting an estimated $89.7M.
- 339 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2016, down from 345 in Q4 2015.
- Funds reported $7.07B of Jazz Pharmaceuticals stock for Q1 2016, down 11% quarter-over-quarter.
- 49 funds opened new Jazz Pharmaceuticals positions in Q1 2016 and 52 closed out, a net change of -3 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2016 was Fidelity International, an estimated $104M added.
- The largest Jazz Pharmaceuticals seller in Q1 2016 was Herndon Capital Management, an estimated $89.7M sold.
Based on aggregated 13F filings for Q1 2016.